{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:31:28Z","timestamp":1794853888452,"version":"4.9.1"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1038\/s41581-022-00661-1","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T19:02:59Z","timestamp":1672945379000},"page":"194-211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":158,"title":["Clinical practice recommendations for primary hyperoxaluria: an\u00a0expert consensus statement from ERKNet and OxalEurope"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8467-3506","authenticated-orcid":false,"given":"Jaap W.","family":"Groothoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Metry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Deesker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Garrelfs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Acquaviva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reham","family":"Almardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0495-7670","authenticated-orcid":false,"given":"Bodo B.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3957-1359","authenticated-orcid":false,"given":"Olivia","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1971-5044","authenticated-orcid":false,"given":"Rimante","family":"Cerkauskiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-022X","authenticated-orcid":false,"given":"Pietro Manuel","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luitzen A.","family":"Groen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asheeta","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Knebelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0849-2225","authenticated-orcid":false,"given":"Giorgia","family":"Mandrile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabbir S.","family":"Moochhala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Prytula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovana","family":"Putnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3223-3752","authenticated-orcid":false,"given":"Gill","family":"Rumsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neveen A.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6248-6478","authenticated-orcid":false,"given":"Bhaskar","family":"Somani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0578-2529","authenticated-orcid":false,"given":"Justine","family":"Bacchetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"key":"661_CR1","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/ndt\/gfs078","volume":"27","author":"P Cochat","year":"2012","unstructured":"Cochat, P. et al. Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol. Dial. Transpl. 27, 1729\u20131736 (2012).","journal-title":"Nephrol. Dial. Transpl."},{"key":"661_CR2","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.kint.2019.08.018","volume":"96","author":"SF Garrelfs","year":"2019","unstructured":"Garrelfs, S. F. et al. Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney Int. 96, 1389\u20131399 (2019).","journal-title":"Kidney Int."},{"key":"661_CR3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.kint.2021.03.031","volume":"100","author":"C Martin-Higueras","year":"2021","unstructured":"Martin-Higueras, C. et al. A report from the European Hyperoxaluria Consortium (OxalEurope) registry on a large cohort of patients with primary hyperoxaluria type 3. Kidney Int. 100, 621\u2013635 (2021).","journal-title":"Kidney Int."},{"key":"661_CR4","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1542\/peds.2004-1260","volume":"114","author":"Steering Committee on Quality Improvement Management.","year":"2004","unstructured":"Steering Committee on Quality Improvement Management. Classifying recommendations for clinical practice guidelines. Pediatrics 114, 874\u2013877 (2004).","journal-title":"Pediatrics"},{"key":"661_CR5","unstructured":"Linstone, H. A. & Turoff, M. The Delphi Method (Addison-Wesley, 1975)."},{"key":"661_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-022-05613-2","author":"G Mandrile","year":"2022","unstructured":"Mandrile, G. et al. Genetic assessment in primary hyperoxaluria: why it matters. Pediatr. Nephrol. https:\/\/doi.org\/10.1007\/s00467-022-05613-2 (2022).","journal-title":"Pediatr. Nephrol."},{"key":"661_CR7","unstructured":"ACGS. Best Practice Guidelines https:\/\/www.acgs.uk.com\/quality\/best-practice-guidelines\/ (2022)"},{"key":"661_CR8","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1523-1755.2004.00842.x","volume":"66","author":"G Rumsby","year":"2004","unstructured":"Rumsby, G., Williams, E. & Coulter-Mackie, M. B. Evaluation of mutation screening as a first line test for the diagnosis of the primary hyperoxalurias. Kidney Int. 66, 959\u2013963 (2004).","journal-title":"Kidney Int."},{"key":"661_CR9","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1681\/ASN.2014070698","volume":"26","author":"K Hopp","year":"2015","unstructured":"Hopp, K. et al. Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J. Am. Soc. Nephrol. 26, 2559\u20132570 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"661_CR10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/ki.2009.435","volume":"77","author":"J Harambat","year":"2010","unstructured":"Harambat, J. et al. Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int. 77, 443\u2013449 (2010).","journal-title":"Kidney Int."},{"key":"661_CR11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00240-020-01201-x","volume":"49","author":"F Zhao","year":"2021","unstructured":"Zhao, F. et al. Characteristics of the genotype and phenotype in Chinese primary hyperoxaluria type 1 populations. Urolithiasis 49, 17\u201325 (2021).","journal-title":"Urolithiasis"},{"key":"661_CR12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00240-017-0996-8","volume":"46","author":"JJ Talati","year":"2018","unstructured":"Talati, J. J. et al. Primary hyperoxaluria in populations of Pakistan origin: results from a literature review and two major registries. Urolithiasis 46, 187\u2013195 (2018).","journal-title":"Urolithiasis"},{"key":"661_CR13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ajhg.2010.07.023","volume":"87","author":"R Belostotsky","year":"2010","unstructured":"Belostotsky, R. et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am. J. Hum. Genet. 87, 392\u2013399 (2010).","journal-title":"Am. J. Hum. Genet."},{"key":"661_CR14","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00467-019-04279-7","volume":"34","author":"X Fang","year":"2019","unstructured":"Fang, X. et al. Nine novel HOGA1 gene mutations identified in primary hyperoxaluria type 3 and distinct clinical and biochemical characteristics in Chinese children. Pediatr. Nephrol. 34, 1785\u20131790 (2019).","journal-title":"Pediatr. Nephrol."},{"key":"661_CR15","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ki.2014.222","volume":"86","author":"G Mandrile","year":"2014","unstructured":"Mandrile, G. et al. Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int. 86, 1197\u20131204 (2014).","journal-title":"Kidney Int."},{"key":"661_CR16","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ekir.2022.04.012","volume":"7","author":"LJ Deesker","year":"2022","unstructured":"Deesker, L. J. et al. Improved outcome of infantile oxalosis over time in Europe: data from the OxalEurope Registry. Kidney Int. Rep. 7, 1608\u20131618 (2022).","journal-title":"Kidney Int. Rep."},{"key":"661_CR17","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/ndt\/gfab027","volume":"37","author":"P Singh","year":"2022","unstructured":"Singh, P. et al. Clinical characterization of primary hyperoxaluria type 3 in comparison to types 1 and 2: a retrospective cohort study. Nephrol. Dial. Transplant. 37, 869\u2013875 (2022).","journal-title":"Nephrol. Dial. Transplant."},{"key":"661_CR18","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cca.2007.06.007","volume":"384","author":"CS van Woerden","year":"2007","unstructured":"van Woerden, C. S., Huidekoper, H. H., Groothoff, J. W., Wijburg, F. A. & Duran, M. Postponing urine acidification for 24 h does not change the oxalate concentration. Clin. Chim. Acta 384, 184\u2013185 (2007).","journal-title":"Clin. Chim. Acta"},{"key":"661_CR19","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/clinchem\/30.8.1339","volume":"30","author":"BC Mazzachi","year":"1984","unstructured":"Mazzachi, B. C., Teubner, J. K. & Ryall, R. L. Factors affecting measurement of urinary oxalate. Clin. Chem. 30, 1339\u20131343 (1984).","journal-title":"Clin. Chem."},{"key":"661_CR20","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/ndt\/gfab306","volume":"37","author":"PM Ferraro","year":"2022","unstructured":"Ferraro, P. M. et al. Estimating 24-hour urinary excretion using spot urine measurements in kidney stone formers. Nephrol. Dial. Transplant. 37, 2171\u20132179 (2022).","journal-title":"Nephrol. Dial. Transplant."},{"key":"661_CR21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/0004563214529937","volume":"52","author":"O Clifford-Mobley","year":"2015","unstructured":"Clifford-Mobley, O., Tims, C. & Rumsby, G. The comparability of oxalate excretion and oxalate:creatinine ratio in the investigation of primary hyperoxaluria:a review of data from a referral centre. Ann. Clin. Biochem. 52, 113\u2013121 (2015).","journal-title":"Ann. Clin. Biochem."},{"key":"661_CR22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s004670050366","volume":"11","author":"B Hoppe","year":"1997","unstructured":"Hoppe, B. et al. Influence of nutrition on urinary oxalate and calcium in preterm and term infants. Pediatr. Nephrol. 11, 687\u2013690 (1997).","journal-title":"Pediatr. Nephrol."},{"key":"661_CR23","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s11255-018-1939-1","volume":"50","author":"R Siener","year":"2018","unstructured":"Siener, R., Hoppe, B., L\u00f6hr, P., M\u00fcller, S. C. & Latz, S. Metabolic profile and impact of diet in patients with primary hyperoxaluria. Int. Urol. Nephrol. 50, 1583\u20131589 (2018).","journal-title":"Int. Urol. Nephrol."},{"key":"661_CR24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2215\/CJN.08000520","volume":"16","author":"C Witting","year":"2021","unstructured":"Witting, C. et al. Pathophysiology and treatment of enteric hyperoxaluria. Clin. J. Am. Soc. Nephrol. 16, 487\u2013495 (2021).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"661_CR25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJMoa010369","volume":"346","author":"L Borghi","year":"2002","unstructured":"Borghi, L. et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N. Engl. J. Med. 346, 77\u201384 (2002).","journal-title":"N. Engl. J. Med."},{"key":"661_CR26","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","volume":"384","author":"SF Garrelfs","year":"2021","unstructured":"Garrelfs, S. F. et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N. Engl. J. Med. 384, 1216\u20131226 (2021).","journal-title":"N. Engl. J. Med."},{"key":"661_CR27","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1177\/000456329102800615","volume":"28","author":"ZE Balchin","year":"1991","unstructured":"Balchin, Z. E., Moss, P. A. & Fraser, C. G. Biological variation of urinary oxalate in different specimen types. Ann. Clin. Biochem. 28, 622\u2013623 (1991).","journal-title":"Ann. Clin. Biochem."},{"key":"661_CR28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00240-016-0860-2","volume":"44","author":"O Clifford-Mobley","year":"2016","unstructured":"Clifford-Mobley, O., Sjogren, A., Lindner, E. & Rumsby, G. Urine oxalate biological variation in patients with primary hyperoxaluria. Urolithiasis 44, 333\u2013337 (2016).","journal-title":"Urolithiasis"},{"key":"661_CR29","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.ekir.2018.07.020","volume":"3","author":"N Lumlertgul","year":"2018","unstructured":"Lumlertgul, N., Siribamrungwong, M., Jaber, B. L. & Susantitaphong, P. Secondary oxalate nephropathy: a systematic review. Kidney Int. Rep. 3, 1363\u20131372 (2018).","journal-title":"Kidney Int. Rep."},{"key":"661_CR30","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/0004563217739035","volume":"55","author":"DJ Marshall","year":"2018","unstructured":"Marshall, D. J., Adaway, J. E. & Keevil, B. G. A combined liquid chromatography tandem mass spectrometry assay for the quantification of urinary oxalate and citrate in patients with nephrolithiasis. Ann. Clin. Biochem. 55, 461\u2013468 (2018).","journal-title":"Ann. Clin. Biochem."},{"key":"661_CR31","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/jmedgenet-2014-102529","volume":"51","author":"Y Frishberg","year":"2014","unstructured":"Frishberg, Y., Zeharia, A., Lyakhovetsky, R., Bargal, R. & Belostotsky, R. Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria. J. Med. Genet. 51, 526\u2013529 (2014).","journal-title":"J. Med. Genet."},{"key":"661_CR32","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.54363","volume":"9","author":"TL McGregor","year":"2020","unstructured":"McGregor, T. L. et al. Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria. eLife 9, e54363 (2020).","journal-title":"eLife"},{"key":"661_CR33","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00467-017-3741-1","volume":"32","author":"O Clifford-Mobley","year":"2017","unstructured":"Clifford-Mobley, O. et al. Glycolate oxidase deficiency in a patient with congenital hyperinsulinism and unexplained hyperoxaluria. Pediatr. Nephrol. 32, 2159\u20132163 (2017).","journal-title":"Pediatr. Nephrol."},{"key":"661_CR34","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/0004563215606158","volume":"53","author":"O Clifford-Mobley","year":"2016","unstructured":"Clifford-Mobley, O., Hewitt, L. & Rumsby, G. Simultaneous analysis of urinary metabolites for preliminary identification of primary hyperoxaluria. Ann. Clin. Biochem. 53, 485\u2013494 (2016).","journal-title":"Ann. Clin. Biochem."},{"key":"661_CR35","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00467-017-3731-3","volume":"32","author":"A Ventzke","year":"2017","unstructured":"Ventzke, A. et al. Systematic assessment of urinary hydroxy-oxo-glutarate for diagnosis and follow-up of primary hyperoxaluria type III. Pediatr. Nephrol. 32, 2263\u20132271 (2017).","journal-title":"Pediatr. Nephrol."},{"key":"661_CR36","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/0004563218811365","volume":"56","author":"G Woodward","year":"2019","unstructured":"Woodward, G., Pryke, R., Hoppe, B. & Rumsby, G. Rapid liquid chromatography tandem mass-spectrometry screening method for urinary metabolites of primary hyperoxaluria. Ann. Clin. Biochem. 56, 232\u2013239 (2019).","journal-title":"Ann. Clin. Biochem."},{"key":"661_CR37","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00240-020-01197-4","volume":"48","author":"F Stokes","year":"2020","unstructured":"Stokes, F. et al. Plasma oxalate: comparison of methodologies. Urolithiasis 48, 473\u2013480 (2020).","journal-title":"Urolithiasis"},{"key":"661_CR38","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.clinbiochem.2017.07.017","volume":"50","author":"M Perinpam","year":"2017","unstructured":"Perinpam, M. et al. Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease. Clin. Biochem. 50, 1014\u20131019 (2017).","journal-title":"Clin. Biochem."},{"key":"661_CR39","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1056\/NEJMra1301564","volume":"369","author":"P Cochat","year":"2013","unstructured":"Cochat, P. & Rumsby, G. Primary hyperoxaluria. N. Engl. J. Med. 369, 649\u2013658 (2013).","journal-title":"N. Engl. J. Med."},{"key":"661_CR40","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1042\/cs0810483","volume":"81","author":"M Marangella","year":"1991","unstructured":"Marangella, M. et al. Serum calcium oxalate saturation in patients on maintenance haemodialysis for primary hyperoxaluria or oxalosis-unrelated renal diseases. Clin. Sci. 81, 483\u2013490 (1991).","journal-title":"Clin. Sci."},{"key":"661_CR41","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1046\/j.1523-1755.1999.00546.x","volume":"56","author":"B Hoppe","year":"1999","unstructured":"Hoppe, B. et al. Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int. 56, 268\u2013274 (1999).","journal-title":"Kidney Int."},{"key":"661_CR42","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.ekir.2020.08.029","volume":"5","author":"A Pfau","year":"2020","unstructured":"Pfau, A. et al. Assessment of plasma oxalate concentration in patients with CKD. Kidney Int. Rep. 5, 2013\u20132020 (2020).","journal-title":"Kidney Int. Rep."},{"key":"661_CR43","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1056\/NEJMc0800990","volume":"359","author":"M Daudon","year":"2008","unstructured":"Daudon, M., Jungers, P. & Bazin, D. Peculiar morphology of stones in primary hyperoxaluria. N. Engl. J. Med. 359, 100\u2013102 (2008).","journal-title":"N. Engl. J. Med."},{"key":"661_CR44","doi-asserted-by":"crossref","first-page":"p31","DOI":"10.1159\/000080261","volume":"98","author":"M Daudon","year":"2004","unstructured":"Daudon, M. & Jungers, P. Clinical value of crystalluria and quantitative morphoconstitutional analysis of urinary calculi. Nephron Physiol. 98, p31\u2013p36 (2004).","journal-title":"Nephron Physiol."},{"key":"661_CR45","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.kint.2020.06.035","volume":"99","author":"A Servais","year":"2021","unstructured":"Servais, A. et al. Cystinuria: clinical practice recommendation. Kidney Int. 99, 48\u201358 (2021).","journal-title":"Kidney Int."},{"key":"661_CR46","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1111\/j.1523-1755.2005.00292.x","volume":"67","author":"M Daudon","year":"2005","unstructured":"Daudon, M., Hennequin, C., Boujelben, G., Lacour, B. & Jungers, P. Serial crystalluria determination and the risk of recurrence in calcium stone formers. Kidney Int. 67, 1934\u20131943 (2005).","journal-title":"Kidney Int."},{"key":"661_CR47","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1046\/j.1523-1755.1998.00876.x","volume":"53","author":"P Jouvet","year":"1998","unstructured":"Jouvet, P. et al. Crystalluria: a clinically useful investigation in children with primary hyperoxaluria post-transplantation. Kidney Int. 53, 1412\u20131416 (1998).","journal-title":"Kidney Int."},{"key":"661_CR48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7326\/0003-4819-93-1-36","volume":"93","author":"CY Pak","year":"1980","unstructured":"Pak, C. Y., Sakhaee, K., Crowther, C. & Brinkley, L. Evidence justifying a high fluid intake in treatment of nephrolithiasis. Ann. Intern. Med. 93, 36\u201339 (1980).","journal-title":"Ann. Intern. Med."},{"key":"661_CR49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00240-018-1041-2","volume":"47","author":"T Porowski","year":"2019","unstructured":"Porowski, T. et al. Upper metastable limit osmolality of urine as a predictor of kidney stone formation in children. Urolithiasis 47, 155\u2013163 (2019).","journal-title":"Urolithiasis"},{"key":"661_CR50","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00467-004-1779-3","volume":"20","author":"MB Lande","year":"2005","unstructured":"Lande, M. B., Varade, W., Erkan, E., Niederbracht, Y. & Schwartz, G. J. Role of urinary supersaturation in the evaluation of children with urolithiasis. Pediatr. Nephrol. 20, 491\u2013494 (2005).","journal-title":"Pediatr. Nephrol."},{"key":"661_CR51","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.eururo.2014.10.029","volume":"67","author":"A Skolarikos","year":"2015","unstructured":"Skolarikos, A. et al. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur. Urol. 67, 750\u2013763 (2015).","journal-title":"Eur. Urol."},{"key":"661_CR52","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF00864405","volume":"7","author":"E Leumann","year":"1993","unstructured":"Leumann, E., Hoppe, B. & Neuhaus, T. Management of primary hyperoxaluria: efficacy of oral citrate administration. Pediatr. Nephrol. 7, 207\u2013211 (1993).","journal-title":"Pediatr. Nephrol."},{"key":"661_CR53","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/ki.2009.237","volume":"76","author":"S Fargue","year":"2009","unstructured":"Fargue, S. et al. Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1. Kidney Int. 76, 767\u2013773 (2009).","journal-title":"Kidney Int."},{"key":"661_CR54","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/ki.2008.63","volume":"73","author":"P Sikora","year":"2008","unstructured":"Sikora, P. et al. [13C2]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria. Kidney Int. 73, 1181\u20131186 (2008).","journal-title":"Kidney Int."},{"key":"661_CR55","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/j.1523-1755.2005.00267.x","volume":"67","author":"CG Monico","year":"2005","unstructured":"Monico, C. G., Rossetti, S., Olson, J. B. & Milliner, D. S. Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int. 67, 1704\u20131709 (2005).","journal-title":"Kidney Int."},{"key":"661_CR56","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000085411","volume":"25","author":"CG Monico","year":"2005","unstructured":"Monico, C. G., Olson, J. B. & Milliner, D. S. Implications of genotype and enzyme phenotype in pyridoxine response of patients with type I primary hyperoxaluria. Am. J. Nephrol. 25, 183\u2013188 (2005).","journal-title":"Am. J. Nephrol."},{"key":"661_CR57","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJM199412083312304","volume":"331","author":"DS Milliner","year":"1994","unstructured":"Milliner, D. S., Eickholt, J. T., Bergstralh, E. J., Wilson, D. M. & Smith, L. H. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N. Engl. J. Med. 331, 1553\u20131558 (1994).","journal-title":"N. Engl. J. Med."},{"key":"661_CR58","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2215\/CJN.06820613","volume":"9","author":"H Hoyer-Kuhn","year":"2014","unstructured":"Hoyer-Kuhn, H. et al. Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice. Clin. J. Am. Soc. Nephrol. 9, 468\u2013477 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"661_CR59","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000086358","volume":"25","author":"B Hoppe","year":"2005","unstructured":"Hoppe, B., Latta, K., von Schnakenburg, C. & Kemper, M. J. Primary hyperoxaluria\u2013the German experience. Am. J. Nephrol. 25, 276\u2013281 (2005).","journal-title":"Am. J. Nephrol."},{"key":"661_CR60","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ki.2009.32","volume":"75","author":"B Hoppe","year":"2009","unstructured":"Hoppe, B., Beck, B. B. & Milliner, D. S. The primary hyperoxalurias. Kidney Int. 75, 1264\u20131271 (2009).","journal-title":"Kidney Int."},{"key":"661_CR61","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1681\/ASN.V1291986","volume":"12","author":"E Leumann","year":"2001","unstructured":"Leumann, E. & Hoppe, B. The primary hyperoxalurias. J. Am. Soc. Nephrol. 12, 1986\u20131993 (2001).","journal-title":"J. Am. Soc. Nephrol."},{"key":"661_CR62","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.ekir.2020.04.004","volume":"5","author":"P Singh","year":"2020","unstructured":"Singh, P. et al. Pyridoxine responsiveness in a type 1 primary hyperoxaluria patient with a rare (atypical) AGXT gene mutation. Kidney Int. Rep. 5, 955\u2013958 (2020).","journal-title":"Kidney Int. Rep."},{"key":"661_CR63","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1523-1755.2004.00796.x","volume":"66","author":"CS van Woerden","year":"2004","unstructured":"van Woerden, C. S. et al. Clinical implications of mutation analysis in primary hyperoxaluria type 1. Kidney Int. 66, 746\u2013752 (2004).","journal-title":"Kidney Int."},{"key":"661_CR64","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0272-6386(12)80833-X","volume":"19","author":"M Marangella","year":"1992","unstructured":"Marangella, M., Petrarulo, M., Cosseddu, D., Vitale, C. & Linari, F. Oxalate balance studies in patients on hemodialysis for type I primary hyperoxaluria. Am. J. Kidney Dis. 19, 546\u2013553 (1992).","journal-title":"Am. J. Kidney Dis."},{"key":"661_CR65","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s004670050145","volume":"10","author":"B Hoppe","year":"1996","unstructured":"Hoppe, B. et al. Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure. Pediatr. Nephrol. 10, 488\u2013492 (1996).","journal-title":"Pediatr. Nephrol."},{"key":"661_CR66","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1038\/sj.ki.5001806","volume":"70","author":"F Illies","year":"2006","unstructured":"Illies, F., Bonzel, K. E., Wingen, A. M., Latta, K. & Hoyer, P. F. Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int. 70, 1642\u20131648 (2006).","journal-title":"Kidney Int."},{"key":"661_CR67","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/ndt\/gfh971","volume":"20","author":"CF Franssen","year":"2005","unstructured":"Franssen, C. F. Oxalate clearance by haemodialysis\u2013a comparison of seven dialysers. Nephrol. Dial. Transpl. 20, 1916\u20131921 (2005).","journal-title":"Nephrol. Dial. Transpl."},{"key":"661_CR68","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00240-005-0004-6","volume":"34","author":"Y Ogawa","year":"2006","unstructured":"Ogawa, Y. et al. Calcium oxalate saturation in dialysis patients with and without primary hyperoxaluria. Urol. Res. 34, 12\u201316 (2006).","journal-title":"Urol. Res."},{"key":"661_CR69","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/ki.1995.283","volume":"48","author":"M Marangella","year":"1995","unstructured":"Marangella, M. et al. Bony content of oxalate in patients with primary hyperoxaluria or oxalosis-unrelated renal failure. Kidney Int. 48, 182\u2013187 (1995).","journal-title":"Kidney Int."},{"key":"661_CR70","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1526-0968.2004.00106.x","volume":"8","author":"C D\u00edaz","year":"2004","unstructured":"D\u00edaz, C. et al. Long daily hemodialysis sessions correct systemic complications of oxalosis prior to combined liver-kidney transplantation: case report. Ther. Apher. Dial. 8, 52\u201355 (2004).","journal-title":"Ther. Apher. Dial."},{"key":"661_CR71","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000360624","volume":"39","author":"X Tang","year":"2014","unstructured":"Tang, X. et al. Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria. Am. J. Nephrol. 39, 376\u2013382 (2014).","journal-title":"Am. J. Nephrol."},{"key":"661_CR72","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/ajt.12535","volume":"14","author":"JF Trotter","year":"2014","unstructured":"Trotter, J. F. & Milliner, D. Auxiliary liver transplant is an ineffective treatment of primary hyperoxaluria. Am. J. Transpl. 14, 241 (2014).","journal-title":"Am. J. Transpl."},{"key":"661_CR73","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/nep.12325","volume":"19","author":"M Knotek","year":"2014","unstructured":"Knotek, M. et al. Combined auxiliary split liver and kidney transplantation for type I primary hyperoxaluria and end-stage kidney disease. Nephrology 19, 814\u2013815 (2014).","journal-title":"Nephrology"},{"key":"661_CR74","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.tp.0000168147.88707.80","volume":"80","author":"N Onaca","year":"2005","unstructured":"Onaca, N. et al. Cadaveric orthotopic auxiliary split liver transplantation and kidney transplantation: an alternative for type 1 primary hyperoxaluria. Transplantation 80, 421\u2013424 (2005).","journal-title":"Transplantation"},{"key":"661_CR75","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1111\/ajt.12381","volume":"13","author":"N Elias","year":"2013","unstructured":"Elias, N. et al. Native portal vein embolization for persistent hyperoxaluria following kidney and auxiliary partial liver transplantation. Am. J. Transpl. 13, 2739\u20132742 (2013).","journal-title":"Am. J. Transpl."},{"key":"661_CR76","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s00467-021-05043-6","volume":"36","author":"EL Metry","year":"2021","unstructured":"Metry, E. L. et al. Transplantation outcomes in patients with primary hyperoxaluria: a systematic review. Pediatr. Nephrol. 36, 2217\u20132226 (2021).","journal-title":"Pediatr. Nephrol."},{"key":"661_CR77","first-page":"1475","volume":"20","author":"P Compagnon","year":"2014","unstructured":"Compagnon, P. et al. Long-term results of combined liver-kidney transplantation for primary hyperoxaluria type 1: the French experience. Liver Transpl. 20, 1475\u20131485 (2014).","journal-title":"Liver Transpl."},{"key":"661_CR78","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1053\/jlts.2001.28741","volume":"7","author":"CG Monico","year":"2001","unstructured":"Monico, C. G. & Milliner, D. S. Combined liver-kidney and kidney-alone transplantation in primary hyperoxaluria. Liver Transpl. 7, 954\u2013963 (2001).","journal-title":"Liver Transpl."},{"key":"661_CR79","doi-asserted-by":"crossref","first-page":"458","DOI":"10.2215\/CJN.07430711","volume":"7","author":"J Harambat","year":"2012","unstructured":"Harambat, J. et al. Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin. J. Am. Soc. Nephrol. 7, 458\u2013465 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"661_CR80","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1111\/j.1600-6143.2010.03271.x","volume":"10","author":"EJ Bergstralh","year":"2010","unstructured":"Bergstralh, E. J. et al. Transplantation outcomes in primary hyperoxaluria. Am. J. Transpl. 10, 2493\u20132501 (2010).","journal-title":"Am. J. Transpl."},{"key":"661_CR81","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/00007890-200209150-00020","volume":"74","author":"DM Cibrik","year":"2002","unstructured":"Cibrik, D. M., Kaplan, B., Arndorfer, J. A. & Meier-Kriesche, H. U. Renal allograft survival in patients with oxalosis. Transplantation 74, 707\u2013710 (2002).","journal-title":"Transplantation"},{"key":"661_CR82","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ekir.2021.11.006","volume":"7","author":"EL Metry","year":"2022","unstructured":"Metry, E. L. et al. Long-Term transplantation outcomes in patients with primary hyperoxaluria type 1 included in the European Hyperoxaluria Consortium (OxalEurope) registry. Kidney Int. Rep. 7, 210\u2013220 (2022).","journal-title":"Kidney Int. Rep."},{"key":"661_CR83","doi-asserted-by":"crossref","first-page":"E69","DOI":"10.1111\/petr.12240","volume":"18","author":"G Naderi","year":"2014","unstructured":"Naderi, G., Latif, A., Tabassomi, F. & Esfahani, S. T. Failure of isolated kidney transplantation in a pediatric patient with primary hyperoxaluria type 2. Pediatr. Transpl. 18, E69\u2013E73 (2014).","journal-title":"Pediatr. Transpl."},{"key":"661_CR84","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/ajt.14418","volume":"18","author":"T Dhondup","year":"2018","unstructured":"Dhondup, T., Lorenz, E. C., Milliner, D. S. & Lieske, J. C. Combined liver-kidney transplantation for primary hyperoxaluria type 2: a case report. Am. J. Transpl. 18, 253\u2013257 (2018).","journal-title":"Am. J. Transpl."},{"key":"661_CR85","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1111\/ajt.15829","volume":"20","author":"A Del Bello","year":"2020","unstructured":"Del Bello, A., Cointault, O., Delas, A. & Kamar, N. Primary hyperoxaluria type 2 successfully treated with combined liver-kidney transplantation after failure of isolated kidney transplantation. Am. J. Transpl. 20, 1752\u20131753 (2020).","journal-title":"Am. J. Transpl."},{"key":"661_CR86","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.asjsur.2021.08.066","volume":"45","author":"Z Jia","year":"2022","unstructured":"Jia, Z., Zhong, Q., Lin, T. & Song, T. Subsequent liver transplantation did not reverse recurrence of oxalate nephropathy after isolated kidney transplantation for primary type 2 hyperoxaluria. Asian J. Surg. 45, 483\u2013485 (2022).","journal-title":"Asian J. Surg."},{"key":"661_CR87","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam (2022)."},{"key":"661_CR88","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00467-013-2424-9","volume":"28","author":"E Al-Abadi","year":"2013","unstructured":"Al-Abadi, E. & Hulton, S. A. Extracorporal shock wave lithotripsy in the management of stones in children with oxalosis\u2013still the first choice? Pediatr. Nephrol. 28, 1085\u20131089 (2013).","journal-title":"Pediatr. Nephrol."},{"key":"661_CR89","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.urology.2014.11.018","volume":"85","author":"A Carrasco Jr","year":"2015","unstructured":"Carrasco, A. Jr, Granberg, C. F., Gettman, M. T., Milliner, D. S. & Krambeck, A. E. Surgical management of stone disease in patients with primary hyperoxaluria. Urology 85, 522\u2013526 (2015).","journal-title":"Urology"},{"key":"661_CR90","first-page":"59","volume":"18","author":"A Kamoun","year":"1997","unstructured":"Kamoun, A. et al. Primary hyperoxaluria: Tunisian experience apropos of 24 pediatric cases [French]. Nephrologie 18, 59\u201364 (1997).","journal-title":"Nephrologie"},{"key":"661_CR91","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/0929-693X(96)81244-9","volume":"2","author":"A Kamoun","year":"1995","unstructured":"Kamoun, A. et al. Value of extracorporeal shockwave lithotripsy in primary hyperoxaluria type I [French]. Arch. Pediatr. 2, 747\u2013749 (1995).","journal-title":"Arch. Pediatr."},{"key":"661_CR92","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/014107688808101019","volume":"81","author":"SA Boddy","year":"1988","unstructured":"Boddy, S. A., Duffy, P. G., Barratt, T. M. & Whitfield, H. N. Hyperoxaluria and renal calculi in children: the role of extracorporeal shock wave lithotripsy. J. R. Soc. Med. 81, 604\u2013605 (1988).","journal-title":"J. R. Soc. Med."},{"key":"661_CR93","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/EJA.0000000000001599","volume":"39","author":"P Frykholm","year":"2022","unstructured":"Frykholm, P. et al. Pre-operative fasting in children: a guideline from the European Society of Anaesthesiology and Intensive Care. Eur. J. Anaesthesiol. 39, 4\u201325 (2022).","journal-title":"Eur. J. Anaesthesiol."},{"key":"661_CR94","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/ki.2014.298","volume":"87","author":"X Tang","year":"2015","unstructured":"Tang, X. et al. Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria. Kidney Int. 87, 623\u2013631 (2015).","journal-title":"Kidney Int."},{"key":"661_CR95","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00240-005-0490-6","volume":"33","author":"TJ Vrtiska","year":"2005","unstructured":"Vrtiska, T. J. Quantitation of stone burden: imaging advances. Urol. Res. 33, 398\u2013402 (2005).","journal-title":"Urol. Res."},{"key":"661_CR96","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.nephro.2016.08.002","volume":"13","author":"NA Soliman","year":"2017","unstructured":"Soliman, N. A. et al. Clinical spectrum of primary hyperoxaluria type 1: experience of a tertiary center. Nephrol. Ther. 13, 176\u2013182 (2017).","journal-title":"Nephrol. Ther."},{"key":"661_CR97","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4103\/1319-2442.182389","volume":"27","author":"M Jellouli","year":"2016","unstructured":"Jellouli, M. et al. Primary hyperoxaluria in infants. Saudi J. Kidney Dis. Transpl. 27, 526\u2013532 (2016).","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"661_CR98","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1093\/ndt\/gfs320","volume":"27","author":"SM van der Hoeven","year":"2012","unstructured":"van der Hoeven, S. M., van Woerden, C. S. & Groothoff, J. W. Primary hyperoxaluria type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort. Nephrol. Dial. Transpl. 27, 3855\u20133862 (2012).","journal-title":"Nephrol. Dial. Transpl."},{"key":"661_CR99","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/ndt\/gfaa210","volume":"36","author":"SA Bakkaloglu","year":"2021","unstructured":"Bakkaloglu, S. A. et al. Bone evaluation in paediatric chronic kidney disease: clinical practice points from the European Society for Paediatric Nephrology CKD-MBD and Dialysis working groups and CKD-MBD working group of the ERA-EDTA. Nephrol. Dial. Transpl. 36, 413\u2013425 (2021).","journal-title":"Nephrol. Dial. Transpl."},{"key":"661_CR100","unstructured":"Devresse, A. et al. 12-Month analysis of ILLUMINATE-A, a phase 3 study of lumasiran: sustained oxalate lowering and kidney stone event rates in primary hyperoxaluria type 1. Presented at Belgian society of Nephrology (2021)."},{"key":"661_CR101","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.gim.2021.10.024","volume":"24","author":"DJ Sas","year":"2022","unstructured":"Sas, D. J. et al. Phase 3 trial of lumasiran for primary hyperoxaluria type 1: a new RNAi therapeutic in infants and young children. Genet. Med. 24, 654\u2013662 (2022).","journal-title":"Genet. Med."},{"key":"661_CR102","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2022.05.012","author":"M Michael","year":"2022","unstructured":"Michael, M. et al. Lumasiran for advanced primary hyperoxaluria type 1: phase 3 ILLUMINATE-C trial. Am. J. Kidney Dis. https:\/\/doi.org\/10.1053\/j.ajkd.2022.05.012 (2022).","journal-title":"Am. J. Kidney Dis."},{"key":"661_CR103","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.kint.2021.08.015","volume":"101","author":"B Hoppe","year":"2022","unstructured":"Hoppe, B. et al. Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria. Kidney Int. 101, 626\u2013634 (2022).","journal-title":"Kidney Int."},{"key":"661_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.07.025","author":"MA Baum","year":"2022","unstructured":"Baum, M. A. et al. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2022.07.025 (2022).","journal-title":"Kidney Int."},{"key":"661_CR105","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.urology.2021.03.014","volume":"156","author":"K Shee","year":"2021","unstructured":"Shee, K. et al. Nedosiran dramatically reduces serum oxalate in dialysis-dependent primary hyperoxaluria 1: a compassionate use case report. Urology 156, e147\u2013e149 (2021).","journal-title":"Urology"},{"key":"661_CR106","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ekir.2021.12.001","volume":"7","author":"SA Hulton","year":"2022","unstructured":"Hulton, S. A. et al. Randomized clinical trial on the long-term efficacy and safety of lumasiran in patients with primary hyperoxaluria type 1. Kidney Int. Rep. 7, 494\u2013506 (2022).","journal-title":"Kidney Int. Rep."},{"key":"661_CR107","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.kint.2021.10.022","volume":"101","author":"N Joher","year":"2022","unstructured":"Joher, N. et al. Early post-transplant recurrence of oxalate nephropathy in a patient with primary hyperoxaluria type 1, despite pretransplant lumasiran therapy. Kidney Int. 101, 185\u2013186 (2022).","journal-title":"Kidney Int."},{"key":"661_CR108","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.kint.2022.04.043","volume":"102","author":"EL Metry","year":"2022","unstructured":"Metry, E. L., Oosterveld, M. J. S., Groothoff, J. W. & Bacchetta, J. The appearance of oxalate crystals in a kidney biopsy is no proof of post-transplant oxalate nephropathy in primary hyperoxaluria type 1. Kidney Int. 102, 446 (2022).","journal-title":"Kidney Int."},{"key":"661_CR109","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1111\/ajt.16762","volume":"21","author":"HK Stone","year":"2021","unstructured":"Stone, H. K. et al. Primary hyperoxaluria diagnosed after kidney transplant: a review of the literature and case report of aggressive renal replacement therapy and lumasiran to prevent allograft loss. Am. J. Transpl. 21, 4061\u20134067 (2021).","journal-title":"Am. J. Transpl."},{"key":"661_CR110","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac295","author":"AL Sellier-Leclerc","year":"2022","unstructured":"Sellier-Leclerc, A. L. et al. Isolated kidney transplantation under lumasiran therapy in primary hyperoxaluria type 1: a report of 5 cases. Nephrol. Dial. Transpl. https:\/\/doi.org\/10.1093\/ndt\/gfac295 (2022).","journal-title":"Nephrol. Dial. Transpl."},{"key":"661_CR111","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00467-016-3324-6","volume":"31","author":"R Duclaux-Loras","year":"2016","unstructured":"Duclaux-Loras, R. et al. Pediatric combined liver-kidney transplantation: a single-center experience of 18 cases. Pediatr. Nephrol. 31, 1517\u20131529 (2016).","journal-title":"Pediatr. Nephrol."},{"key":"661_CR112","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1172\/JCI99822","volume":"129","author":"M Le Dudal","year":"2019","unstructured":"Le Dudal, M. et al. Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoning. J. Clin. Invest. 129, 2571\u20132577 (2019).","journal-title":"J. Clin. Invest."},{"key":"661_CR113","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40620-021-01116-9","volume":"35","author":"P Violier","year":"2022","unstructured":"Violier, P., Boyer, O., Berthaud, R. & Dorval, G. Treatment with stiripentol in a patient with primary hyperoxaluria type 1: lesson for the clinical nephrologist. J. Nephrol. 35, 1049\u20131051 (2022).","journal-title":"J. Nephrol."},{"key":"661_CR114","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ckj\/sfaa068","volume":"14","author":"C Martin-Higueras","year":"2021","unstructured":"Martin-Higueras, C., Feldkotter, M. & Hoppe, B. Is stiripentol truly effective for treating primary hyperoxaluria? Clin. Kidney J. 14, 442\u2013444 (2021).","journal-title":"Clin. Kidney J."},{"key":"661_CR115","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00467-020-04585-5","volume":"35","author":"C Kempf","year":"2020","unstructured":"Kempf, C. et al. Stiripentol fails to lower plasma oxalate in a dialysis-dependent PH1 patient. Pediatr. Nephrol. 35, 1787\u20131789 (2020).","journal-title":"Pediatr. Nephrol."},{"key":"661_CR116","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03819647 (2021)."},{"key":"661_CR117","doi-asserted-by":"crossref","first-page":"i33","DOI":"10.1093\/ckj\/sfab203","volume":"15","author":"NA Soliman","year":"2022","unstructured":"Soliman, N. A. & Mabrouk, S. Primary hyperoxaluria type 1 in developing countries: novel challenges in a new therapeutic era. Clin. Kidney J. 15, i33\u2013i36 (2022).","journal-title":"Clin. Kidney J."},{"key":"661_CR118","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0022-3476(99)70095-8","volume":"135","author":"P Cochat","year":"1999","unstructured":"Cochat, P. et al. Primary hyperoxaluria in infants: medical, ethical, and economic issues. J. Pediatr. 135, 746\u2013750 (1999).","journal-title":"J. Pediatr."},{"key":"661_CR119","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/s12882-021-02546-0","volume":"22","author":"Z Cai","year":"2021","unstructured":"Cai, Z. et al. Primary hyperoxaluria diagnosed after kidney transplantation: a case report and literature review. BMC Nephrol. 22, 393 (2021).","journal-title":"BMC Nephrol."},{"key":"661_CR120","doi-asserted-by":"crossref","first-page":"634175","DOI":"10.1155\/2015\/634175","volume":"2015","author":"MS Al Riyami","year":"2015","unstructured":"Al Riyami, M. S., Al Ghaithi, B., Al Hashmi, N. & Al Kalbani, N. Primary hyperoxaluria type 1 in 18 children: genotyping and outcome. Int. J. Nephrol. 2015, 634175 (2015).","journal-title":"Int. J. Nephrol."},{"key":"661_CR121","first-page":"119","volume":"7","author":"RI Almardini","year":"2014","unstructured":"Almardini, R. I., Alfarah, M. G. & Salaita, G. M. The clinical pattern of primary hyperoxaluria in pediatric patient at Queen Rania Abdulla Children Hospital. Arab. J. Nephrol. Transpl. 7, 119\u2013123 (2014).","journal-title":"Arab. J. Nephrol. Transpl."},{"key":"661_CR122","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4103\/1319-2442.100885","volume":"23","author":"T Gargah","year":"2012","unstructured":"Gargah, T. et al. Primary hyperoxaluria type 1 in Tunisian children. Saudi J. Kidney Dis. Transpl. 23, 385\u2013390 (2012).","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"661_CR123","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1089\/gtmb.2015.0136","volume":"19","author":"L Boualla","year":"2015","unstructured":"Boualla, L. et al. AGXT gene mutations and prevalence of primary hyperoxaluria type 1 in Moroccan population. Genet. Test. Mol. Biomark. 19, 623\u2013628 (2015).","journal-title":"Genet. Test. Mol. Biomark."},{"key":"661_CR124","doi-asserted-by":"crossref","DOI":"10.1186\/s12920-021-00996-x","volume":"14","author":"H Murad","year":"2021","unstructured":"Murad, H. et al. Molecular analysis of the AGXT gene in Syrian patients suspected with primary hyperoxaluria type 1. BMC Med. Genomics 14, 146 (2021).","journal-title":"BMC Med. Genomics"},{"key":"661_CR125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ahg.12178","volume":"81","author":"S M\u2019Dimegh","year":"2017","unstructured":"M\u2019Dimegh, S. et al. Mutational analysis of agxt in Tunisian population with primary hyperoxaluria type 1. Ann. Hum. Genet. 81, 1\u201310 (2017).","journal-title":"Ann. Hum. Genet."},{"key":"661_CR126","volume":"12","author":"NA Soliman","year":"2022","unstructured":"Soliman, N. A. et al. Clinical and molecular characterization of primary hyperoxaluria in Egypt. Sci. Rep. 12, 15886 (2022).","journal-title":"Sci. Rep."},{"key":"661_CR127","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrneph.2012.113","volume":"8","author":"B Hoppe","year":"2012","unstructured":"Hoppe, B. An update on primary hyperoxaluria. Nat. Rev. Nephrol. 8, 467\u2013475 (2012).","journal-title":"Nat. Rev. Nephrol."},{"key":"661_CR128","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.ekir.2020.09.022","volume":"5","author":"A Devresse","year":"2020","unstructured":"Devresse, A., Cochat, P., Godefroid, N. & Kanaan, N. Transplantation for primary hyperoxaluria type 1: designing new strategies in the era of promising therapeutic perspectives. Kidney Int. Rep. 5, 2136\u20132145 (2020).","journal-title":"Kidney Int. Rep."},{"key":"661_CR129","doi-asserted-by":"crossref","first-page":"14406","DOI":"10.1073\/pnas.1408401111","volume":"111","author":"N Miyata","year":"2014","unstructured":"Miyata, N. et al. Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1. Proc. Natl Acad. Sci. USA 111, 14406\u201314411 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"661_CR130","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1681\/ASN.2021060729","volume":"32","author":"S Garrelfs","year":"2021","unstructured":"Garrelfs, S. et al. Endogenous oxalate production in primary hyperoxaluria type 1 patients. J. Am. Soc. Nephrol. 32, 3175\u20133186 (2021).","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-022-00661-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-022-00661-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-022-00661-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T14:12:16Z","timestamp":1676902336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-022-00661-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":130,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["661"],"URL":"https:\/\/doi.org\/10.1038\/s41581-022-00661-1","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,5]]},"assertion":[{"value":"23 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.W.F. has received study grants for stable isotope and registry studies from Alnylam, Dicerna and UniQure and commissions for advisory board work and presentations for Alnylam. All these payments were made to the Research unit; no personal payments were accepted. J.W.F is also chair of the Steering Committee of OxalEurope and vice-chair of the metabolic working group of ERKNet. S.G. received study grants from Alnylam. C.A. has received consulting fees from Alnylam. B.B.B. has received consultation fees from Alnylam Pharmaceuticals and is a member of the scientific advisory board of the German PH self-support group PH Selbsthilfe e.V. O.B. has received consultancy fees and travel grants from Alnylam and Biocodex. P.M.F. has received consultant fees and grant\/other support from Allena Pharmaceuticals, Alnylam, Amgen, AstraZeneca, BioHealth Italia, Gilead, Otsuka Pharmaceuticals, Rocchetta, Vifor Fresenius, and royalties as an author for UpToDate. J.B. has received consulting fees from Alnylam, Dicerna, Amgen, Bayer, Biocordex and Amolyt, and honoraria for presentations from Alnylam, Alexion, Bayer and Kyowa Kirin. J.B., B.B.B and S.S.M. are members of the Steering Committee of OxalEurope. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}